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OL-043 Multiple drug resistance from single lamivudine
therapy after adefovir treatment failure in
chronic hepatitis B patients
S. Yang1 *, J.M. Zheng1, X.Y. Wang1, Q. Wang1, H.C. Xing1,
W. Xie1, J. Cheng1. 1Beijing Ditan Hospital, Capital Medical
University, China
Objectives: To investigate the multiple drug resistance
(MDR) proﬁles in patients who took sequential therapy after
adefovir treatment failure.
Methods: 210 patients’ clinical data and serum samples
who took sequential lamivudine therapy as rescue therapy
after adefovir treatment failure were collected from 5
hospitals in China during December 2007 to December 2009.
PCR product population sequencing was used for screening
MDR. PCR product cloning sequencing were used for further
analyzing resistance proﬁles.
Results: 3 MDR patients were identiﬁed with population
sequencing. All 3 patients are genotype C patients.
Population sequencing showed rtM204V + rtL180M +rtA181V
mutation in all 3 patients. And 64 clones were get from
3 patients. Cloning sequencing results were showed in
Chart1. All clones carried mutations resistant to lamivudine
and adefovir. rtM204V + rtL180M +rtA181V is the major
mutation type in 3 MDR patients (67.2%). Besides, all 3
patients carried clones with entecavir resistance mutation
(rtM250V/H, rtS202I, rtI169V), though in minority (23.4%).
Conclusions: Single lamivudine as rescue therapy for
adefovir treatment failure may cause MDR. rtM204V +
rtL180M + rtA181V is the major form of mutation in these
patients. Entecavir resistance mutation maybe induced with
sequential therapy.
Chart 1. Cloning sequencing of 3 MDR chronic hepatitis B patients
Treatment history Mutations Number
ADV(36m)→ LAM(12m) M204V+A181V+L180M 19
M204I+A181T
M204V+A181T 1
M204V+A181V+L180M+M250V 11
ADV(36m)→ LAM(15m) M204V+A181V+L180M 8
M204V+A181V+L180M+S202I 1
M204I+A181T 1
M204V+A181V 1
ADV(12m)→ LAM(12m) M204V+A181V+L180M 16
M204V+A181V+L180M+I169V 1
M204V+A181V+L180M+M250V 1
M204V+A181V+L180M+M250H 1
M204V+A181I 1
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Aim: To investigate the model for end-stage liver disease
(MELD), Child Turcotte Pugh (CTP), Mayo, end-stage liver
disease score to serum sodium ratio (MESO) and MELD with
incorporation of serum sodium (MELD-Na) score in predicting
the short-term prognosis of patients with ACHBLF.
Methods: Data from 226 patients admitted due to ACHBLF
were reviewed. The ability of ﬁve score systems to predict
the prognosis of ACHBLF were compared with the receive
operating characteristic curve (ROC).
Result: The MELD, CTP, Mayo, MESO, MELD-Na scores
in death group (30.2±9.2, 11.3±1.4, 10.4±1.2, 2.3±0.7
and 38.0±11.8, respectively) were higher than those in
survival group (21.0±6.8, 10.6±1.6, 9.0±1.6, 1.5±0.5 and
22.5±8.2, respectively) (all P< 0.01). The area under the
ROC (AUC) of ﬁve score systems were 0.809, 0.616, 0.759,
0.828 and 0.874, respectively (Figure 1, Table 1). The
Youden’s indexes were 0.501, 0.183, 0.413, 0.520 and 0.632,
respectively.
Conclusion: MELD-Na is more appropriate in predicting
short-term mortality, but larger scale studies are needed
to conﬁrm the superiority of MELD-Na to MELD, Mayo, MESO
and CTP in patients with ACHBLF.
Figure 1. Comparison of the predictive accuracy of the ﬁve
models to predict 3-month mortality of acute-on-chronic
hepatitis B liver failure.
Table 1
Items Z statistics P value
CTP vs. Mayo 4.32 <0.001
CTP vs. MELD 4.20 <0.001
CTP vs. MELD-Na 6.16 <0.001
CTP vs. MESO 4.76 <0.001
Mayo vs. MELD 1.38 0.168
Mayo vs. MELD-Na 3.44 0.001
Mayo vs. MESO 1.99 0.046
MELD vs. MELD-Na 3.14 0.002
MELD vs. MESO 2.70 0.007
MESO vs. MELD-Na 2.83 0.005
